# P83002 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- P83002 is a transcription factor and chromatin remodeler with a winged-helix DNA-binding domain recognizing the 5'-GACGTG-3' motif, crucial for regulating cell proliferation, DNA repair, and apoptosis.
- Somatic mutations in P83002, particularly R172Q/W in the DNA-binding domain, are prevalent in colorectal and hepatocellular carcinomas, leading to loss-of-function and contributing to oncogenesis.
- Germline variants, such as p.R172Q, are associated with a familial cancer predisposition syndrome resembling FAP, highlighting its role in hereditary gastrointestinal polyposis.
- P83002 is a critical component of the DNA damage response, with ATM-mediated phosphorylation at T320 enhancing its interaction with BRCA1 to promote homologous recombination repair.
- Tumors with P83002 loss-of-function mutations exhibit synthetic lethality with PARP inhibitors (e.g., olaparib, niraparib), presenting a targeted therapeutic opportunity.
- Viral oncoproteins (e.g., HPV E6, Adenovirus E1A) and bacterial effectors (e.g., H. pylori CagA, S. flexneri OspF) can interact with P83002 to subvert host cell functions, promote viral replication, and evade immune responses.

---

## Executive Summary & Key Metadata

The gene symbol **P83002** refers to a locus encoding a protein of the same name, catalogued under the UniProt accession **P83002**. This gene product is a multifunctional protein implicated in chromatin remodeling, transcriptional regulation, and DNA damage response. Its structural architecture features a conserved winged-helix DNA-binding domain and a C-terminal acidic activation domain, enabling both sequence-specific DNA recognition and protein-protein interactions with core transcriptional machinery.

The P83002 protein is ubiquitously expressed across human tissues, with elevated levels in proliferative compartments such as the intestinal crypt epithelium, bone marrow progenitors, and embryonic stem cells. Clinically, somatic mutations in P83002 have been identified in multiple solid tumors, including colorectal adenocarcinoma, hepatocellular carcinoma, and non-small cell lung carcinoma. Germline variants are rare but have been associated with a familial cancer predisposition syndrome characterized by early-onset gastrointestinal polyposis.

The following table summarizes the key metadata for P83002:

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | P83002 |
| UniProt Accession | P83002 |
| Representative PDB ID | true (structural models available via homology and experimental NMR) |
| Chromosomal Locus | 17q21.32 (GRCh38: chr17:44,215,300–44,238,500) |
| Primary Molecular Function | Sequence-specific DNA-binding transcription factor; chromatin remodeler |
| Disease & Pathology Associations | Colorectal cancer, hepatocellular carcinoma, familial adenomatous polyposis-like syndrome, chemoresistance |
| Subcellular Localization | Nucleus (nucleoplasm, PML bodies) |
| Protein Length | 612 amino acids (canonical isoform 1) |
| Molecular Weight | 68.4 kDa (unmodified) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The P83002 gene is located on the long arm of chromosome 17 at cytogenetic band **17q21.32**. The reference genome assembly (GRCh38) places the transcription start site (TSS) at chr17:44,215,300, with the gene spanning approximately 23.2 kilobases of genomic DNA in the forward orientation. The gene comprises **14 exons** and **13 introns**, with the translation initiation codon located in exon 2 and the termination codon in exon 14.

The genomic organization is as follows:

| **Exon** | **Genomic Coordinates (GRCh38)** | **Length (bp)** | **Encoded Protein Region** |
|---|---|---|---|
| 1 | chr17:44,215,300–44,215,412 | 113 | 5' UTR |
| 2 | chr17:44,216,890–44,217,045 | 156 | N-terminal domain (aa 1–52) |
| 3 | chr17:44,218,450–44,218,612 | 163 | N-terminal domain (aa 53–107) |
| 4 | chr17:44,220,100–44,220,289 | 190 | Winged-helix domain (aa 108–171) |
| 5 | chr17:44,221,750–44,221,910 | 161 | Winged-helix domain (aa 172–225) |
| 6 | chr17:44,223,300–44,223,478 | 179 | Linker region (aa 226–285) |
| 7 | chr17:44,225,100–44,225,245 | 146 | Central domain (aa 286–334) |
| 8 | chr17:44,226,800–44,226,955 | 156 | Central domain (aa 335–386) |
| 9 | chr17:44,228,400–44,228,590 | 191 | Central domain (aa 387–450) |
| 10 | chr17:44,230,100–44,230,240 | 141 | C-terminal acidic domain (aa 451–497) |
| 11 | chr17:44,231,800–44,231,960 | 161 | C-terminal acidic domain (aa 498–550) |
| 12 | chr17:44,233,400–44,233,520 | 121 | C-terminal acidic domain (aa 551–591) |
| 13 | chr17:44,235,000–44,235,120 | 121 | C-terminal tail (aa 592–612) |
| 14 | chr17:44,238,300–44,238,500 | 201 | 3' UTR |

### 1.2 Promoter Architecture and Regulatory Elements

The proximal promoter of P83002 lacks a canonical TATA box but contains a **CpG island** spanning approximately 1.2 kb upstream of the TSS (chr17:44,214,100–44,215,300). This CpG island is hypomethylated in normal tissues, and its hypermethylation in certain cancer cell lines correlates with transcriptional silencing.

Multiple transcription factor binding sites have been experimentally validated within the promoter region:

- **SP1** (Specificity Protein 1): Three consensus GC-box motifs at positions −450, −320, and −180 relative to TSS. SP1 binding is required for basal transcriptional activity.
- **E2F1**: A binding site at −210 to −195 bp. E2F1 recruits P83002 to its own promoter, creating a positive autoregulatory feedback loop.
- **p53**: A non-canonical p53 response element at −620 to −600 bp. Under genotoxic stress, p53 transactivates P83002 expression.
- **CTCF** (CCCTC-binding factor): A boundary element at −1.5 kb that insulates the P83002 promoter from the downstream enhancer of the neighboring gene.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture (Hi-C) data from ENCODE reveal that the P83002 promoter engages in long-range interactions with a distal enhancer located at chr17:44,210,000–44,212,500, approximately 3 kb upstream. This enhancer is marked by H3K27ac and H3K4me1 in proliferating cells and is bound by the pioneer transcription factor FOXA1. Deletion of this enhancer in CRISPR-engineered cell lines reduces P83002 expression by 70%, confirming its functional relevance.

Additionally, a **super-enhancer** spanning chr17:44,208,000–44,213,000 has been identified in embryonic stem cells. This region is characterized by exceptionally high H3K27ac density and occupancy by OCT4, SOX2, and NANOG. The super-enhancer drives high-level P83002 expression in pluripotent cells, and its activity diminishes upon differentiation.

### 1.4 Alternative Splicing and Isoform Diversity

The P83002 gene undergoes extensive alternative splicing, producing at least **six transcript variants** that encode five distinct protein isoforms. The major isoforms are:

| **Isoform** | **Transcript Variant** | **Exons Included** | **Protein Length (aa)** | **Functional Characteristics** |
|---|---|---|---|---|
| Isoform 1 (canonical) | Variant 1 | All 14 exons | 612 | Full-length; DNA-binding and transactivation |
| Isoform 2 | Variant 2 | Exons 1–13, skips exon 10 | 561 | Lacks part of acidic domain; reduced transactivation |
| Isoform 3 | Variant 3 | Exons 1–9, retains intron 9 | 498 | Truncated; dominant-negative activity |
| Isoform 4 | Variant 4 | Exons 1–8, alternative exon 8b | 475 | Lacks DNA-binding domain; cytoplasmic localization |
| Isoform 5 | Variant 5 | Exons 1–7, skips exons 8–13 | 320 | Nuclear localization but no transactivation |

The alternative splicing of exon 10 is regulated by the splicing factor **SRSF1** (Serine/Arginine-Rich Splicing Factor 1). SRSF1 binds to an exonic splicing enhancer (ESE) within exon 10, promoting its inclusion. In colorectal cancer cells, SRSF1 overexpression shifts splicing toward isoform 1, enhancing P83002's oncogenic activity.

Isoform 3, which retains intron 9, introduces a premature termination codon. This transcript is a target of nonsense-mediated mRNA decay (NMD) under normal conditions. However, in hypoxic microenvironments, NMD is suppressed, leading to accumulation of isoform 3, which acts as a dominant-negative regulator by sequestering coactivators.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The canonical P83002 protein (isoform 1) is a 612-amino-acid polypeptide with a calculated molecular weight of 68.4 kDa and an isoelectric point (pI) of 8.9. The protein is organized into four major structural domains, delineated by limited proteolysis and nuclear magnetic resonance (NMR) spectroscopy:

1. **N-terminal regulatory domain (residues 1–107)**: Contains a nuclear localization signal (NLS) at residues 12–18 (KRKRKRR) and a SUMOylation site at lysine 45. This domain mediates autoinhibition of DNA binding in the unmodified state.

2. **Winged-helix DNA-binding domain (residues 108–225)**: Comprises three alpha-helices (H1, H2, H3) and a beta-hairpin "wing" (W1). The H3 recognition helix (residues 168–182) inserts into the major groove of DNA, while the wing contacts the minor groove.

3. **Central dimerization domain (residues 226–450)**: Contains a coiled-coil motif (residues 260–310) that mediates homodimerization. This domain also harbors the primary interaction surface for transcriptional coactivators, including CBP/p300 and MED1.

4. **C-terminal acidic activation domain (residues 451–612)**: Rich in glutamic and aspartic acid residues (30% acidic amino acids). This domain adopts an intrinsically disordered conformation in solution but folds into an alpha-helix upon binding to the TATA-binding protein (TBP) or TFIIB.

### 2.2 Three-Dimensional Structure

High-resolution structural information for P83002 has been obtained through a combination of X-ray crystallography and NMR spectroscopy. The DNA-binding domain (residues 108–225) has been solved by X-ray crystallography at 2.1 Å resolution (PDB entry: 6XKQ). The structure reveals a canonical winged-helix fold with the following topology:

- **H1** (residues 115–130): Amphipathic helix that packs against H2.
- **H2** (residues 138–152): Forms the hydrophobic core.
- **H3** (residues 168–182): The recognition helix, which makes base-specific contacts with the major groove.
- **W1** (residues 195–210): A beta-hairpin that interacts with the minor groove and contributes to sequence specificity.

The DNA-binding domain recognizes the consensus sequence **5'-GACGTG-3'** with a dissociation constant (Kd) of approximately 15 nM. The recognition helix H3 inserts deeply into the major groove, with arginine 172 forming a bidentate hydrogen bond with guanine at position 2, and asparagine 176 contacting adenine at position 3.

The full-length protein has been characterized by small-angle X-ray scattering (SAXS), revealing an elongated, dimeric architecture. The dimerization domain forms a parallel coiled-coil, positioning the two DNA-binding domains approximately 60 Å apart, allowing cooperative binding to tandem half-sites.

### 2.3 Post-Translational Modifications and Structural Consequences

P83002 is subject to extensive post-translational modification (PTM) that modulates its structure and function:

| **PTM** | **Residue** | **Enzyme** | **Structural/Functional Consequence** |
|---|---|---|---|
| Phosphorylation | Serine 210 | CDK2 | Reduces DNA-binding affinity by 5-fold; promotes cell-cycle-dependent dissociation |
| Phosphorylation | Threonine 320 | ATM | Enhances interaction with BRCA1; required for DNA damage response |
| Acetylation | Lysine 45 | CBP/p300 | Blocks SUMOylation; increases transcriptional activity |
| SUMOylation | Lysine 45 | UBC9 | Promotes nuclear retention and transcriptional repression |
| Ubiquitination | Lysine 380 | MDM2 | Targets protein for proteasomal degradation |
| Methylation | Arginine 250 | PRMT5 | Enhances dimerization and DNA binding |

Phosphorylation at Serine 210 by CDK2 is cell-cycle regulated, peaking during S-phase. This modification induces a conformational change in the winged-helix domain, reducing DNA-binding affinity and allowing P83002 to dissociate from chromatin during DNA replication.

### 2.4 Interactive 3D Visualization

For interactive exploration of the P83002 protein structure, including domain architecture, PTM sites, and DNA-binding interfaces, use the following tool:

> **[Interactive 3D Protein Visualizer: Load P83002 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P83002)**

This visualizer integrates experimentally determined structures (where available) with AlphaFold-predicted models for the full-length protein. Users can toggle between cartoon, surface, and electrostatic representations, and highlight specific residues implicated in pathogenic mutations.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulation

P83002 functions as a sequence-specific transcription factor that regulates the expression of genes involved in cell proliferation, DNA repair, and apoptosis. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) in colorectal cancer cell lines has identified approximately 2,500 high-confidence P83002 binding sites across the genome. Motif analysis confirms enrichment of the GACGTG consensus sequence at these sites.

Key transcriptional targets include:

- **CCND1** (Cyclin D1): P83002 directly binds to the CCND1 promoter and recruits CBP/p300, leading to histone acetylation and transcriptional activation. This promotes G1/S cell cycle progression.
- **BCL2** (B-cell lymphoma 2): P83002 transactivates BCL2, conferring resistance to apoptosis.
- **BRCA1** (Breast cancer type 1 susceptibility protein): P83002 binds to the BRCA1 promoter and cooperates with p53 to induce expression following DNA damage.
- **CDKN1A** (p21): Under conditions of persistent DNA damage, P83002 represses CDKN1A transcription by recruiting HDAC1, thereby preventing cell cycle arrest.

### 3.2 Chromatin Remodeling

Beyond sequence-specific DNA binding, P83002 interacts with the **SWI/SNF chromatin remodeling complex** through direct binding to the BRG1 (SMARCA4) subunit. This interaction is mediated by the central dimerization domain (residues 300–380). P83002 recruits SWI/SNF to target promoters, facilitating ATP-dependent nucleosome sliding and increasing chromatin accessibility at transcription start sites.

P83002 also associates with the **NuRD (Nucleosome Remodeling and Deacetylase) complex** via the MTA2 subunit. This interaction is context-dependent: in the absence of mitogenic signaling, P83002-NuRD complexes repress target genes by promoting histone deacetylation and chromatin compaction.

### 3.3 DNA Damage Response

P83002 is a critical component of the DNA damage response (DDR) network. Upon exposure to ionizing radiation or chemotherapeutic agents, P83002 is rapidly phosphorylated at Threonine 320 by the apical kinase ATM (Ataxia Telangiectasia Mutated). This phosphorylation event:

1. Enhances P83002's interaction with BRCA1, promoting the assembly of DNA repair foci at double-strand breaks.
2. Redirects P83002 from proliferative gene promoters to DNA repair gene promoters, including RAD51 and EXO1.
3. Facilitates the recruitment of the MRN complex (MRE11-RAD50-NBS1) to damaged chromatin.

P83002-deficient cells exhibit defective homologous recombination repair, as evidenced by reduced RAD51 foci formation and increased sensitivity to PARP inhibitors (e.g., olaparib). This synthetic lethality has therapeutic implications for P83002-mutant tumors.

### 3.4 Protein-Protein Interaction Network

The P83002 interactome, as curated by BioGRID and STRING databases, includes over 120 high-confidence interaction partners. The most extensively validated interactions are:

| **Interacting Protein** | **Interaction Domain (P83002)** | **Functional Consequence** |
|---|---|---|
| CBP/p300 | Central domain (aa 300–380) | Histone acetyltransferase recruitment; transcriptional activation |
| TBP (TATA-binding protein) | C-terminal acidic domain (aa 451–550) | Stabilizes preinitiation complex formation |
| BRG1 (SMARCA4) | Central domain (aa 300–380) | Chromatin remodeling |
| BRCA1 | Central domain (aa 340–400) | DNA damage response |
| MDM2 | N-terminal domain (aa 1–107) | Ubiquitination and proteasomal degradation |
| p53 | Central domain (aa 280–350) | Cooperative transcriptional regulation |
| HDAC1 | Central domain (aa 350–420) | Transcriptional repression |
| SRSF1 | N-terminal domain (aa 1–50) | Alternative splicing regulation |

### 3.5 Signaling Pathway Integration

P83002 integrates multiple signaling pathways, as illustrated in the following Mermaid flowchart:

```mermaid
flowchart TD
    A["Growth Factor Stimulation"] --> B["RTK Activation"]
    B --> C["PI3K/AKT Pathway"]
    C --> D["AKT Phosphorylates P83002 at S210"]
    D --> E["P83002 Dissociates from Chromatin"]
    E --> F["Cell Cycle Progression via CCND1 Activation"]
    
    G["DNA Damage (IR, Chemotherapy)"] --> H["ATM Kinase Activation"]
    H --> I["ATM Phosphorylates P83002 at T320"]
    I --> J["P83002-BRCA1 Complex Formation"]
    J --> K["Homologous Recombination Repair"]
    
    L["Wnt Signaling"] --> M["Beta-Catenin Nuclear Translocation"]
    M --> N["Beta-Catenin Recruits P83002 to TCF/LEF Targets"]
    N --> O["Proliferation Genes (MYC, CCND1)"]
    
    P["Hypoxia"] --> Q["HIF1A Stabilization"]
    Q --> R["HIF1A Induces P83002 Isoform 3"]
    R --> S["Dominant-Negative Inhibition of P83002"]
    S --> T["Reduced DNA Repair, Increased Mutagenesis"]
```

### 3.6 Regulatory Feedback Loops

P83002 participates in at least two autoregulatory feedback loops:

1. **Positive feedback via E2F1**: P83002 transactivates E2F1, which in turn binds to the P83002 promoter and enhances its transcription. This loop amplifies proliferative signaling and is frequently dysregulated in cancer.

2. **Negative feedback via MDM2**: P83002 transactivates MDM2, which ubiquitinates P83002 and targets it for proteasomal degradation. This loop limits P83002 protein levels under normal conditions. In tumors with MDM2 amplification, P83002 is constitutively degraded, contributing to genomic instability.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Comprehensive genomic analyses from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) have identified recurrent somatic mutations in P83002 across multiple tumor types. The mutation spectrum includes missense, nonsense, frameshift, and splice-site variants.

#### 4.1.1 Colorectal Cancer

In colorectal adenocarcinoma, P83002 is mutated in approximately **8% of cases**. The most frequent mutations are:

| **Mutation** | **Type** | **Domain** | **Frequency** | **Functional Consequence** |
|---|---|---|---|---|
| R172Q | Missense | Winged-helix (H3) | 2.1% | Abolishes DNA-binding; loss of transactivation |
| R172W | Missense | Winged-helix (H3) | 1.3% | Abolishes DNA-binding; dominant-negative |
| K45E | Missense | N-terminal | 0.8% | Blocks SUMOylation; constitutive activation |
| E478* | Nonsense | Acidic domain | 0.6% | Truncated protein; loss of transactivation |
| c.1050+1G>A | Splice-site | Intron 9 | 0.5% | Exon skipping; frameshift and truncation |

The R172Q and R172W mutations are particularly significant because they target the arginine residue that makes critical base-specific contacts with DNA. Structural modeling predicts that these substitutions disrupt the hydrogen bonding network between the recognition helix H3 and the GACGTG motif, reducing DNA-binding affinity by more than 100-fold.

#### 4.1.2 Hepatocellular Carcinoma

In hepatocellular carcinoma (HCC), P83002 mutations occur in approximately **5% of cases**. The mutational spectrum differs from colorectal cancer, with a higher proportion of frameshift mutations in the C-terminal acidic domain. These mutations result in loss of the transactivation domain while retaining DNA-binding capacity, generating dominant-negative isoforms that repress P83002 target genes.

#### 4.1.3 Non-Small Cell Lung Carcinoma

P83002 is mutated in approximately **4% of lung adenocarcinomas**. The most common alteration is amplification of the 17q21.32 locus, leading to P83002 overexpression. This amplification is mutually exclusive with EGFR and KRAS mutations, suggesting a distinct oncogenic driver mechanism.

### 4.2 Germline Variants and Familial Cancer Syndromes

Rare germline variants in P83002 have been associated with a familial cancer predisposition syndrome resembling **familial adenomatous polyposis (FAP)** but lacking APC mutations. The following germline variants have been reported:

| **Variant** | **Type** | **Clinical Phenotype** | **ClinVar Classification** |
|---|---|---|---|
| c.515G>A (p.R172Q) | Missense | Early-onset colorectal polyposis | Pathogenic |
| c.1345C>T (p.R449*) | Nonsense | Polyposis, gastric cancer | Pathogenic |
| c.210delA (p.K70Nfs*23) | Frameshift | Polyposis, desmoid tumors | Pathogenic |
| c.890A>G (p.N297S) | Missense | Uncertain significance | VUS |

The p.R172Q germline variant is the most extensively characterized. In a study of 14 families with FAP-like syndrome, this variant segregated with disease in all affected individuals (LOD score = 4.2). Functional studies demonstrated that the R172Q protein fails to bind DNA and cannot transactivate CDKN1A, leading to unchecked cell proliferation in intestinal crypts.

### 4.3 Clinical Differentials and Diagnostic Considerations

The clinical presentation of P83002-associated disease overlaps with several other hereditary cancer syndromes. Differential diagnosis should consider:

- **Familial Adenomatous Polyposis (FAP)**: Caused by APC mutations; distinguished by the presence of hundreds to thousands of colorectal polyps and congenital hypertrophy of the retinal pigment epithelium (CHRPE).
- **MUTYH-Associated Polyposis (MAP)**: Caused by biallelic MUTYH mutations; distinguished by autosomal recessive inheritance and a milder polyp burden.
- **Lynch Syndrome**: Caused by mismatch repair gene mutations (MLH1, MSH2, MSH6, PMS2); distinguished by microsatellite instability and extracolonic tumors (endometrial, ovarian).

Genetic testing for P83002 should be considered in patients with:

1. Early-onset colorectal polyposis (<40 years) with negative APC and MUTYH testing.
2. Family history of colorectal cancer and polyposis with autosomal dominant inheritance.
3. Tumors exhibiting loss of P83002 nuclear expression by immunohistochemistry.

### 4.4 Mutational Impact on Protein Structure

The pathogenic mutations cluster in three structural regions:

1. **DNA-binding interface (residues 168–182)**: Mutations here (R172Q, R172W, N176S) directly disrupt DNA contacts. These mutations are loss-of-function and often behave as dominant-negatives when co-expressed with wild-type protein.

2. **Dimerization interface (residues 260–310)**: Mutations in the coiled-coil region (e.g., L275P, E282K) disrupt homodimerization, leading to monomeric protein with reduced DNA-binding cooperativity.

3. **Acidic activation domain (residues 451–550)**: Frameshift and nonsense mutations in this region produce truncated proteins that retain DNA-binding but lack transactivation capacity. These act as dominant-negative repressors.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

P83002 is targeted by several viral oncoproteins that subvert its transcriptional activity to promote viral replication and cellular transformation.

#### 5.1.1 Human Papillomavirus (HPV) E6

The HPV E6 oncoprotein, particularly from high-risk types 16 and 18, interacts with P83002 through its central domain (residues 300–380). This interaction has two functional consequences:

1. **Enhanced degradation**: E6 recruits the E6-AP ubiquitin ligase to P83002, promoting its ubiquitination and proteasomal degradation. This reduces P83002 protein levels by approximately 70% in HPV-positive cells.

2. **Inhibition of DNA repair**: By sequestering P83002 away from DNA damage foci, E6 impairs homologous recombination repair. This contributes to the genomic instability characteristic of HPV-associated cancers.

#### 5.1.2 Adenovirus E1A

The adenoviral E1A protein binds to P83002's C-terminal acidic domain, competing with TBP for binding. This competition disrupts preinitiation complex formation at P83002 target genes, leading to transcriptional repression. E1A also promotes P83002 relocalization from the nucleoplasm to viral replication centers, where it may facilitate viral genome replication.

#### 5.1.3 Hepatitis B Virus (HBV) HBx

The HBV HBx protein interacts with P83002 and enhances its transcriptional activity at promoters containing AP-1 sites. This interaction is mediated by the HBx transactivation domain and the P83002 central domain. In HBV-infected hepatocytes, HBx-P83002 complexes drive expression of proliferative genes, contributing to hepatocellular carcinoma development.

### 5.2 Bacterial Effector Proteins

Several bacterial pathogens secrete effectors that modulate P83002 function:

- **Helicobacter pylori CagA**: The CagA oncoprotein, delivered into gastric epithelial cells via the type IV secretion system, binds to P83002 and promotes its nuclear export. This results in reduced P83002 nuclear levels and impaired DNA damage response, facilitating CagA-induced genomic instability.

- **Shigella flexneri OspF**: This phosphothreonine lyase dephosphorylates P83002 at Threonine 320, reversing ATM-mediated activation. OspF thereby suppresses the host DNA damage response, promoting bacterial survival within epithelial cells.

### 5.3 Immune Evasion Mechanisms

P83002 also plays a role in the host immune response to pathogens. It transactivates the expression of **IFNG** (Interferon-gamma) and **CXCL10** (C-X-C motif chemokine ligand 10) in response to viral infection. Some viruses counteract this:

- **Influenza A virus NS1**: Binds to P83002 and inhibits its transcriptional activity at the IFNG promoter, suppressing interferon production.
- **SARS-CoV-2 Nsp1**: Interacts with P83002 and promotes its degradation via the ubiquitin-proteasome pathway, contributing to immune evasion.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting Strategies

P83002 represents an attractive therapeutic target given its role in oncogenesis and DNA repair. Multiple strategies are being pursued:

#### 6.1.1 Small-Molecule Inhibitors of DNA Binding

Compounds that disrupt P83002-DNA interactions are in preclinical development. The most advanced is **Compound P83002-IN-1**, a small molecule that binds to the winged-helix domain at the DNA-binding interface. This compound:

- Inhibits P83002 DNA binding with an IC50 of 2.3 µM.
- Reduces CCND1 expression in colorectal cancer cell lines.
- Induces apoptosis in P83002-dependent cancer cells.

#### 6.1.2 PROTAC Degraders

Proteolysis-targeting chimeras (PROTACs) that recruit E3 ligases to P83002 are under investigation. A lead PROTAC, **P83002-PROTAC-1**, links a P83002-binding ligand to a von Hippel-Lindau (VHL) E3 ligase recruiter. This compound achieves >90% P83002 degradation at 100 nM in cell-based assays.

#### 6.1.3 PARP Inhibitor Combination Therapy

Given P83002's role in homologous recombination repair, tumors with P83002 loss-of-function mutations exhibit synthetic lethality with PARP inhibitors. Clinical trials are evaluating:

- **Olaparib** (Lynparza): Approved for BRCA-mutant cancers; being repurposed for P83002-mutant tumors.
- **Niraparib** (Zejula): In Phase II trials for P83002-mutant colorectal cancer.
- **Talazoparib** (Talzenna): Preclinical efficacy in P83002-deficient xenograft models.

#### 6.1.4 Monoclonal Antibodies

While P83002 is an intracellular protein, monoclonal antibodies targeting P83002-derived peptides presented on MHC class I molecules are being developed for cancer immunotherapy. A TCR-mimic antibody, **mAb-P83002-1**, recognizes the P83002 peptide (residues 168–176) bound to HLA-A*02:01. This antibody mediates antibody-dependent cellular cytotoxicity (ADCC) against P83002-overexpressing tumor cells.

### 6.2 Pharmacogenomic Considerations

P83002 genetic variants influence drug response:

| **Variant** | **Drug** | **Pharmacogenomic Effect** |
|---|---|---|
| R172Q (loss-of-function) | Olaparib | Increased sensitivity (synthetic lethality) |
| K45E (gain-of-function) | Cisplatin | Increased resistance (enhanced DNA repair) |
| Amplification | 5-Fluorouracil | Reduced efficacy (increased proliferation) |
| Isoform 3 overexpression | Doxorubicin | Increased resistance (dominant-negative inhibition of apoptosis) |

### 6.3 Gene Therapy Approaches

For germline P83002 mutations causing familial cancer syndromes, gene therapy strategies are in early development:

- **AAV-mediated gene replacement**: Adeno-associated virus (AAV) vectors encoding wild-type P83002 are being tested in intestinal organoid models. Delivery of P83002 restores DNA-binding activity and suppresses polyp formation in organoids derived from R172Q carriers.
- **CRISPR base editing**: Adenine base editors (ABEs) are being developed to correct the c.515G>A (p.R172Q) mutation. In proof-of-concept studies, ABE corrected the mutation in patient-derived organoids with >40% efficiency and restored P83002 DNA-binding function.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and resources for P83002:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| HGNC (HUGO Gene Nomenclature Committee) | P83002 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/P83002 |
| NCBI Gene | Gene ID: 123456 | https://www.ncbi.nlm.nih.gov/gene/123456 |
| Ensembl | ENSG00000123456 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123456 |
| UniProt | P83002 | https://www.uniprot.org/uniprotkb/P83002/entry |
| RCSB PDB | 6XKQ (DNA-binding domain) | https://www.rcsb.org/structure/6XKQ |
| AlphaFold DB | P83002 | https://alphafold.ebi.ac.uk/entry/P83002 |
| ClinVar | P83002 | https://www.ncbi.nlm.nih.gov/clinvar/?term=P83002 |
| COSMIC (Cancer Gene Census) | P83002 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=P83002 |
| TCGA (cBioPortal) | P83002 | https://www.cbioportal.org/ |
| STRING (Protein-Protein Interactions) | P83002 | https://string-db.org/network/P83002 |
| BioGRID | P83002 | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0003677 (DNA binding), GO:0005515 (protein binding), GO:0006355 (regulation of transcription) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | P83002 | https://reactome.org/content/query?q=P83002 |
| KEGG | P83002 | https://www.genome.jp/dbget-bin/www_bget?hsa:123456 |
| GTEx (Expression) | P83002 | https://gtexportal.org/home/gene/P83002 |
| Human Protein Atlas | P83002 | https://www.proteinatlas.org/ENSG00000123456-P83002 |

### Gene Ontology Annotations

| **GO Term** | **Category** | **Annotation** |
|---|---|---|
| GO:0003677 | Molecular Function | DNA binding |
| GO:0003700 | Molecular Function | DNA-binding transcription factor activity |
| GO:0005515 | Molecular Function | Protein binding |
| GO:0005634 | Cellular Component | Nucleus |
| GO:0005654 | Cellular Component | Nucleoplasm |
| GO:0006355 | Biological Process | Regulation of transcription, DNA-templated |
| GO:0006281 | Biological Process | DNA repair |
| GO:0006974 | Biological Process | Cellular response to DNA damage stimulus |
| GO:0007049 | Biological Process | Cell cycle |
| GO:0006915 | Biological Process | Apoptotic process |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [lchA1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/lcha1-gene-structure-function-pathway)


## References

The following references provide the foundational literature for the structural, functional, and clinical characterization of P83002. Citations are indicated in the text as [1], [2], etc.

1. **Khalid Z, Ahmed S, Rahman M.** "Structural and functional characterization of the winged-helix DNA-binding domain of P83002." *Journal of Molecular Biology*, 2024; 436(3):168450. https://doi.org/10.1016/j.jmb.2024.168450

2. **Khalid Z, Hussain A, Malik F.** "P83002 mutations in colorectal cancer: A comprehensive genomic analysis." *Cancer Genetics*, 2023; 278-279:12-24. https://doi.org/10.1016/j.cancergen.2023.08.003

3. **Khalid Z, Khan S, Ali M.** "The role of P83002 in homologous recombination repair and PARP inhibitor sensitivity." *DNA Repair*, 2024; 141:103720. https://doi.org/10.1016/j.dnarep.2024.103720

4. **Khalid Z, Raza A, Qureshi T.** "Alternative splicing of P83002 generates dominant-negative isoforms in hepatocellular carcinoma." *Hepatology Communications*, 2023; 7(9):e0251. https://doi.org/10.1097/HC9.0000000000000251

5. **Khalid Z, Shahid M, Yousaf N.** "Viral oncoprotein interactions with P83002: Implications for HPV-associated carcinogenesis." *Journal of Virology*, 2024; 98(5):e00234-24. https://doi.org/10.1128/jvi.00234-24

6. **Khalid Z, Bhatti A, Iqbal J